Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 301 - 325 of 386

  1. Greene WC. Proceedings of the AACR 1987. IL-2, IL-2 receptors and human retroviruses. 1987; 469-470.
  2. Chanda PK, Chen GF, Baine Y, Leonard WJ, Greene WC, Chang TW, Chang NT. Expression of human interleukin-2 receptor cDNA in E. coli. Biochem Biophys Res Commun. 1986 Dec 15; 141(2):804-11.
  3. Neckers LM, Bauer S, McGlennen RC, Trepel JB, Rao K, Greene WC. Diltiazem inhibits transferrin receptor expression and causes G1 arrest in normal and neoplastic T cells. Mol Cell Biol. 1986 Dec; 6(12):4244-50.
  4. Greene WC. Characterization of the human interleukin 2 receptor at the DNA, RNA, and protein level. Immunobiology. 1986 Sep; 172(3-5):357-64.
  5. In: Greene WC, moderator. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T lymphotropic retroviruses. Ann. Int. Med. Deregulated interleukin-2 receptor expression in Adult T-cell Leukemia. 1986; 105:566-569.
  6. Greene WC, Leonard WJ, Wano Y, Sodroski JG, Rosen CA, Haseltine WA. In: Marget M, Lang W, Gabler-Sandberger E (Eds.), Proceedings of the IXth International Congress of Infectious and Parasitic Diseases. The transactivator (tat) gene of HTLV-II activates IL-2 receptor, IL-2, and class II major histocompatibility complex cellular gene expression. 1986; 1:67-69.
  7. Depper JM, Leonard WJ, Greene WC. In: Pincus S, Pisetsky D, Rosenwasser L (Eds.), Biologically based immunomodulators in the therapy of rheumatic diseases. The human receptor for interleukin-2: characterization, controversies, and expression in rheumatic diseases. 1986; 297-306.
  8. Greene WC, Depper JM, Krönke M, Leonard WJ. The human interleukin-2 receptor: analysis of structure and function. Immunol Rev. 1986 Aug; 92:29-48.
  9. Krönke M, Schlick E, Waldmann TA, Vitetta ES, Greene WC. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. Cancer Res. 1986 Jul; 46(7):3295-8.
  10. Treiger BF, Leonard WJ, Svetlik P, Rubin LA, Nelson DL, Greene WC. A secreted form of the human interleukin 2 receptor encoded by an "anchor minus" cDNA. J Immunol. 1986 Jun 01; 136(11):4099-105.
  11. Greene WC, Leonard WJ, Wano Y, Svetlik PB, Peffer NJ, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Science. 1986 May 16; 232(4752):877-80.
  12. Weissman AM, Harford JB, Svetlik PB, Leonard WL, Depper JM, Waldmann TA, Greene WC, Klausner RD. Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci U S A. 1986 Mar; 83(5):1463-6.
  13. Greene WC, Leonard WJ, Depper JM. Growth of human T lymphocytes: an analysis of interleukin 2 and its cellular receptor. Prog Hematol. 1986; 14:283-301.
  14. In: Greene WC, moderator. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T lymphotropic retroviruses. Ann. Int. Med. Deregulated interleukin-2 receptor expression in Adult T-cell Leukemia. 1986; 105:566-569.
  15. Greene WC, Leonard WJ, Wano Y, Sodroski JG, Rosen CA, Haseltine WA. In: Marget M, Lang W, Gabler-Sandberger E (Eds.), Proceedings of the IXth International Congress of Infectious and Parasitic Diseases. The transactivator (tat) gene of HTLV-II activates IL-2 receptor, IL-2, and class II major histocompatibility complex cellular gene expression. 1986; 1:67-69.
  16. Depper JM, Leonard WJ, Greene WC. In: Pincus S, Pisetsky D, Rosenwasser L (Eds.), Biologically based immunomodulators in the therapy of rheumatic diseases. The human receptor for interleukin-2: characterization, controversies, and expression in rheumatic diseases. 1986; 297-306.
  17. Waldmann TA, Korsmeyer SJ, Greene WC. The arrangement of immunoglobulin, T cell antigen receptor, and interleukin 2 receptor genes in human lymphoid neoplasms. Symp Fundam Cancer Res. 1986; 38:63-78.
  18. Greene WC, Leonard WJ. The human interleukin-2 receptor. Annu Rev Immunol. 1986; 4:69-95.
  19. Greene WC, Depper JM, Krönke M, Leonard WJ. The human interleukin-2 receptor: role in normal T-cell growth and association with HTLV-I-induced T-cell leukemia. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:731-7.
  20. Leonard WJ, Depper JM, Kanehisa M, Krönke M, Peffer NJ, Svetlik PB, Sullivan M, Greene WC. Structure of the human interleukin-2 receptor gene. Science. 1985 Nov 08; 230(4726):633-9.
  21. Reed JC, Greene WC, Hoover RG, Nowell PC. Monoclonal antibody OKT11A inhibits and recombinant interleukin 2 (IL 2) augments expression of IL 2 receptors at a pretranslational level. J Immunol. 1985 Oct; 135(4):2478-82.
  22. Waldmann TA, Longo DL, Leonard WJ, Depper JM, Thompson CB, Krönke M, Goldman CK, Sharrow S, Bongiovanni K, Greene WC. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res. 1985 Sep; 45(9 Suppl):4559s-4562s.
  23. Leonard WJ, Krönke M, Peffer NJ, Depper JM, Greene WC. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci U S A. 1985 Sep; 82(18):6281-5.
  24. Greene WC, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, Krönke M, Svetlik P, Peffer NJ, Waldmann TA. Isolation and expression of complementary DNAs encoding the human interleukin 2 receptor. Cancer Res. 1985 Sep; 45(9 Suppl):4563s-4567s.
  25. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 1985 Jul 11; 313(2):79-84.